Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

Vaccine

Volumn 26, Issue 26, 2008, Pages 3252-3260

  Dorgham, Karim ^a,b   Abadie, Valérie ^a,b   Iga, Mutsunori ^a,b   Hartley, Oliver ^d   Gorochov, Guy ^a,b,c   Combadière, Behazine ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

CCR5 superagonist; DNA vaccine; Genetic adjuvant; Tumor vaccine

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DNA VACCINE; IMMUNOGLOBULIN 1P7; OVALBUMIN; PLASMID DNA; RANTES;

ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; IMMUNOSTIMULATION; INOCULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL5; FEMALE; MICE; MICE, INBRED C57BL; OVALBUMIN; RECEPTORS, CCR5; VACCINATION; VACCINES, DNA;

EID: 44749086303     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.003     Document Type: Article

References (59)

1. Taub D.D., and Oppenheim J.J. Chemokines, inflammation and the immune system. Ther Immunol 1 4 (1994) 229-246
2. Sallusto F., Mackay C.R., and Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 18 (2000) 593-620
3. Luther S.A., and Cyster J.G. Chemokines as regulators of T cell differentiation. Nat Immunol 2 2 (2001) 102-107
4. Esche C., Stellato C., and Beck L.A. Chemokines: key players in innate and adaptive immunity. J Invest Dermatol 125 4 (2005) 615-628
5. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 3 (2003) 203-213
6. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353 25 (2005) 2654-2666
7. Musha H., Ohtani H., Mizoi T., Kinouchi M., Nakayama T., Shiiba K., et al. Selective infiltration of CCR5 (+)CXCR3 (+) T lymphocytes in human colorectal carcinoma. Int J Cancer 116 6 (2005) 949-956
8. Kirk C.J., Hartigan-O'Connor D., and Mule J.J. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61 24 (2001) 8794-8802
9. Kim C.H., Hong M.J., Park S.D., Kim C.K., Park M.Y., Sohn H.J., et al. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother (2006) 1-11
10. Wang L.X., Li R., Yang G., Lim M., O'Hara A., Chu Y., et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 65 22 (2005) 10569-10577
11. Ribas A. Clinical trials with tumor antigen genetically modified dendritic cells. Semin Oncol 32 6 (2005) 556-562
12. Pavlenko M., Leder C., and Pisa P. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Expert Rev Vaccines 4 3 (2005) 315-327
13. Lowe D.B., Shearer M.H., and Kennedy R.C. DNA vaccines: successes and limitations in cancer and infectious disease. J Cell Biochem 98 2 (2006) 235-242
14. Barouch D.H., Santra S., Steenbeke T.D., Zheng X.X., Perry H.C., Davies M.E., et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 161 4 (1998) 1875-1882
15. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A 97 8 (2000) 4192-4197
16. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 16 (2003) 8729-8735
17. Iga M., Boissonnas A., Mahe B., Bonduelle O., Combadiere C., and Combadiere B. Single CX3CL1-Ig DNA administration enhances T cell priming in vivo. Vaccine (2007)
18. Westermann J., Nguyen-Hoai T., Baldenhofer G., Hopken U.E., Lipp M., Dorken B., et al. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther 14 6 (2007) 523-532
19. Elzaouk L., Pavlovic J., and Moelling K. Analysis of antitumor activity elicited by vaccination with combinations of interleukin-12 DNA with gp100 DNA or the chemokine CCL21 in vivo. Hum Gene Ther 17 8 (2006) 859-870
20. Yamano T., Kaneda Y., Hiramatsu S.H., Huang S., Tran A.N., Giuliano A.E., et al. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Ther 14 5 (2007) 451-459
21. Lavergne E., Combadiere C., Iga M., Boissonnas A., Bonduelle O., Maho M., et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 173 6 (2004) 3755-3762
22. Kim J.J., Nottingham L.K., Sin J.I., Tsai A., Morrison L., Oh J., et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 102 6 (1998) 1112-1124
23. Xin K.Q., Lu Y., Hamajima K., Fukushima J., Yang J., Inamura K., et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 92 1 (1999) 90-96
24. Kim S.J., Lee C., Lee S.Y., Kim I., Park J.S., Sasagawa T., et al. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES. Gene Ther 10 15 (2003) 1268-1273
25. Sin J., Kim J.J., Pachuk C., Satishchandran C., and Weiner D.B. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4 (+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 74 23 (2000) 11173-11180
26. Schall T.J., Bacon K., Toy K.J., and Goeddel D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347 6294 (1990) 669-671
27. Kitaura M., Nakajima T., Imai T., Harada S., Combadiere C., Tiffany H.L., et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor CC chemokine receptor 3. J Biol Chem 271 13 (1996) 7725-7730
28. Combadiere C., Ahuja S.K., Tiffany H.L., and Murphy P.M. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1 (alpha), MIP-1 (beta), and RANTES. J Leukoc Biol 60 1 (1996) 147-152
29. Sallusto F., Lenig D., Mackay C.R., and Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187 6 (1998) 875-883
30. Kim C.H., Nagata K., and Butcher E.C. Dendritic cells support sequential reprogramming of chemoattractant receptor profiles during naive to effector T cell differentiation. J Immunol 171 1 (2003) 152-158
31. Boissonnas A., Combadiere C., Lavergne E., Maho M., Blanc C., Debre P., et al. Antigen distribution drives programmed antitumor CD8 cell migration and determines its efficiency. J Immunol 173 1 (2004) 222-229
32. Sozzani S., Locati M., Allavena P., Van Damme J., and Mantovani A. Chemokines: a superfamily of chemotactic cytokines. Int J Clin Lab Res 26 2 (1996) 69-82
33. Devergne O., Marfaing-Koka A., Schall T.J., Leger-Ravet M.B., Sadick M., Peuchmaur M., et al. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and endothelial cells. J Exp Med 179 5 (1994) 1689-1694
34. Hartley O., Dorgham K., Perez-Bercoff D., Cerini F., Heimann A., Gaertner H., et al. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J Virol 77 12 (2003) 6637-6644
35. Zheng X.X., Steele A.W., Nickerson P.W., Steurer W., Steiger J., and Strom T.B. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 154 10 (1995) 5590-5600
36. Wilken J., Hoover D., Thompson D.A., Barlow P.N., McSparron H., Picard L., et al. Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES. Chem Biol 6 1 (1999) 43-51
37. Hartley O., Gaertner H., Wilken J., Thompson D., Fish R., Ramos A., et al. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci U S A 101 47 (2004) 16460-16465
38. Marzo A.L., Kinnear B.F., Lake R.A., Frelinger J.J., Collins E.J., Robinson B.W., et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 165 11 (2000) 6047-6055
39. Rotzschke O., Falk K., Stevanovic S., Jung G., Walden P., and Rammensee H.G. Exact prediction of a natural T cell epitope. Eur J Immunol 21 11 (1991) 2891-2894
40. Barouch D.H., and Letvin N.L. Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys. Dev Biol (Basel) 104 (2000) 85-92
41. Westermann J., Nguyen-Hoai T., Mollweide A., Richter G., Schmetzer O., Kim H.J., et al. Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization. Gene Ther (2004)
42. Biragyn A., Tani K., Grimm M.C., Weeks S., and Kwak L.W. Genetic fusion of chemokines to a self-tumor antigen induces protective T-cell dependent antitumor immunity. Nat Biotechnol 17 3 (1999) 253-258
43. Sin J.I., Kim J.J., Arnold R.L., Shroff K.E., McCallus D., Pachuk C., et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 162 5 (1999) 2912-2921
44. Kusakabe K., Xin K.Q., Katoh H., Sumino K., Hagiwara E., Kawamoto S., et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 164 6 (2000) 3102-3111
45. Eo S.K., Kumaraguru U., and Rouse B.T. Plasmid DNA encoding CCR7 ligands compensate for dysfunctional CD8+ T cell responses by effects on dendritic cells. J Immunol 167 7 (2001) 3592-3599
46. Baek K.M., Ko S.Y., Lee M., Lee J.S., Kim J.O., Ko H.J., et al. Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65. Vaccine 21 25-26 (2003) 3684-3689
47. Kutzler M.A., and Weiner D.B. Developing DNA vaccines that call to dendritic cells. J Clin Invest 114 9 (2004) 1241-1244
48. Kim T.W., Lee J.H., He L., Boyd D.A., Hung C.F., and Wu T.C. DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen. Hum Gene Ther 16 1 (2005) 26-34
49. Frauenschuh A., DeVico A.L., Lim S.P., Gallo R.C., and Garzino-Demo A. Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine 23 4 (2004) 546-554
50. Hartley O., and Offord R.E. Engineering chemokines to develop optimized HIV inhibitors. Curr Protein Pept Sci 6 3 (2005) 207-219
51. Lederman M.M., Veazey R.S., Offord R., Mosier D.E., Dufour J., Mefford M., et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306 5695 (2004) 485-487
52. Restifo N.P., Ying H., Hwang L., and Leitner W.W. The promise of nucleic acid vaccines. Gene Ther 7 2 (2000) 89-92
53. Scheerlinck J.Y. Genetic adjuvants for DNA vaccines. Vaccine 19 17-19 (2001) 2647-2656
54. Shinoda K., Xin K.Q., Kojima Y., Saha S., Okuda K., and Okuda K. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost. Clin Immunol 119 1 (2006) 32-37
55. Sallusto F., Lanzavecchia A., and Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 19 12 (1998) 568-574
56. Vecchi A., Massimiliano L., Ramponi S., Luini W., Bernasconi S., Bonecchi R., et al. Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J Leukoc Biol 66 3 (1999) 489-494
57. Fukada K., Sobao Y., Tomiyama H., Oka S., and Takiguchi M. Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells. J Immunol 168 5 (2002) 2225-2232
58. Molon B., Gri G., Bettella M., Gomez-Mouton C., Lanzavecchia A., Martinez A.C., et al. T cell costimulation by chemokine receptors. Nat Immunol 6 5 (2005) 465-471
59. Aliberti J., Reis e Sousa C., Schito M., Hieny S., Wells T., Huffnagle G.B., et al. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 1 1 (2000) 83-87